The data add to growing evidence supporting the use of HER2 therapy across solid tumors, though researchers find a difficult path to a tissue-agnostic approval.
Treatment biomarkers for small cell lung cancer have been nearly non-existent, but researchers are beginning to find ones that mark PARP inhibitor response.
Pfizer expects its own trial of talazoparib for this new indication to wrap up in 2021, ideally recapitulating the positive results seen in this smaller group.
An international team saw an overall survival benefit when using BRAF, MEK, and EGFR inhibitors together in previously treated, BRAF-mutated metastatic colorectal cancer patients.
A modified analogue of rucaparib is being used to track PARP-1 expression in PARP inhibitor-treated patients with pancreatic, breast, prostate, and other cancer types.
The actual match rate is significantly higher than the 10 percent rate the researchers anticipated they would see when the study began in 2017.
In work presented at the recent American Association for Cancer Research annual meeting, they found that T-cell cytokine production predicted patient response.
Based on the findings, MD Anderson is already using HER2 status to recommend patients for clinical trials instead of EGFR drugs and authors recommend others follow suit.
The VISTA T cell-inhibiting protein found on macrophage immune cells may contribute to poor pancreatic ductal adenocarcinoma outcomes, new research finds.
Using samples from different points in patients' treatment, researchers employed a variety of tools, including NanoString's GeoMx DSP, to explore potential response markers.